UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 110

Sortiert nach

Radiation therapy for locally advanced pancreatic adenocarcinoma: a therapeutic option which should not be forgotten. Letter to the Editor regarding: “Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up” by Huguet et al

Annals of oncology, 2024-08, Vol.35 (8), p.749-750

2024

Volltextzugriff (PDF)

1779P PSMA guided approach for bIoCHEmical relapse after prostatectomy-PSICHE trial

Annals of oncology, 2023-10, Vol.34, p.S961-S962

2023

Volltextzugriff (PDF)

671P Prospective assessment of AR splice variant and PSMA detection on circulating tumour cells of mCRPC patients: Preliminary results of PRIMERA trial (NCT04188275)

Annals of oncology, 2020-09, Vol.31, p.S538-S539

2020

Volltextzugriff (PDF)

978TiP Durvalumab with cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: A phase I/II trial

Annals of oncology, 2020-09, Vol.31, p.S686-S686

2020

Volltextzugriff (PDF)

Stereotactic Ablative Radiotherapy (SART) of Lung Lesion in Oligometastatic Patients: the Importance of High Doses Delivery

Annals of oncology, 2015-04, Vol.26, p.i45

2015

Volltextzugriff (PDF)

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

Annals of oncology, 2014-08, Vol.25 (8), p.1544-1550

2014

Volltextzugriff (PDF)

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

Annals of oncology, 2019-03, Vol.30 (3), p.405-411

2019

Volltextzugriff (PDF)

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Annals of oncology, 2019-03, Vol.30 (3), p.397-404

2019

Volltextzugriff (PDF)

Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy

Annals of oncology, 2019-02, Vol.30 (2), p.236-242

2019

Volltextzugriff (PDF)

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

Annals of oncology, 2015-02, Vol.26 (2), p.259-271

2015

Volltextzugriff (PDF)

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

Annals of oncology, 2021-12, Vol.32 (12), p.1475-1495

2021

Volltextzugriff (PDF)

Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial

Annals of oncology, 2018-04, Vol.29 (4), p.1056-1062

2018

Volltextzugriff (PDF)

First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis

Annals of oncology, 2021-08, Vol.32 (8), p.983-993

2021

Volltextzugriff (PDF)

Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy

Annals of oncology, 2019-12, Vol.30 (12), p.1941-1949

2019

Volltextzugriff (PDF)

Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement

Annals of oncology, 2012-12, Vol.23 (12), p.2997-3006

2012

Volltextzugriff (PDF)

Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis

Annals of oncology, 2022-03, Vol.33 (3), p.321-329

2022

Volltextzugriff (PDF)

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

Annals of oncology, 2016-08, Vol.27 (8), p.1519-1525

2016

Volltextzugriff (PDF)

A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis

Annals of oncology, 2021-05, Vol.32 (5), p.652-660

2021

Volltextzugriff (PDF)

Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers

Annals of oncology, 2016-10, Vol.27 (10), p.1860-1866

2016

Volltextzugriff (PDF)

Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial

Annals of oncology, 2016-06, Vol.27 (6), p.1047-1054

2016

Volltextzugriff (PDF)

Passion for immune checkpoint blockade in triple negative breast cancer: Comment on the IMpassion130 study

Annals of oncology, 2019-01, Vol.30 (1), p.13-16

2019

Volltextzugriff (PDF)

Pertuzumab: new hope for patients with HER2-positive breast cancer

Annals of oncology, 2013-02, Vol.24 (2), p.273-282

2013

Volltextzugriff (PDF)

Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy

Annals of oncology, 2021-10, Vol.32 (10), p.1256-1266

2021

Volltextzugriff (PDF)

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial

Annals of oncology, 2017-01, Vol.28 (1), p.128-135

2017

Volltextzugriff (PDF)

Genomic characterisation of hormone receptor-positive breast cancer arising in very young women

Annals of oncology, 2023-04, Vol.34 (4), p.397-409

2023

Volltextzugriff (PDF)

1 – 25 von 110

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieAnnals Of Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(110)
Mit Volltextzugriff
(110)

Publikationsform

Artikel
(110)

Sprache

Englisch
(110)
Japanisch
(8)

Erscheinungsjahr

n.n

Kollektion

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Radiation therapy for locally advanced pancreatic adenocarcinoma: a therapeutic option which should not be forgotten. Letter to the Editor regarding: “Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up” by Huguet et al

1779P PSMA guided approach for bIoCHEmical relapse after prostatectomy-PSICHE trial

671P Prospective assessment of AR splice variant and PSMA detection on circulating tumour cells of mCRPC patients: Preliminary results of PRIMERA trial (NCT04188275)

978TiP Durvalumab with cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: A phase I/II trial

Stereotactic Ablative Radiotherapy (SART) of Lung Lesion in Oligometastatic Patients: the Importance of High Doses Delivery

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial

First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis

Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy

Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement

Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis

Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers

Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial

Passion for immune checkpoint blockade in triple negative breast cancer: Comment on the IMpassion130 study

Pertuzumab: new hope for patients with HER2-positive breast cancer

Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial

Genomic characterisation of hormone receptor-positive breast cancer arising in very young women

Aktive Filter

Suchergebnisse filtern